Saban Sec
- 専門分野: Clinical oncologist
- 14年の経験
- 話します:Turkish
- 勤務先: トルコ, イスタンブール, Valued Med Hub Hospitals
- Turkish Medical Oncology Association Specialist Physicians Representative since 2022. Member of Istanbul Medical Chamber and Turkish Medical Oncology Association.
Dr. Saban Sec is a medical oncologist with experience at leading hospitals, including Haseki Training and Research Hospital, Prof. Dr. Cemil Taşcıoğlu City Hospital, and Bahçelievler Medikalpark Hospital. He currently represents specialist physicians in the Turkish Medical Oncology Association. He is also a member of the Istanbul Medical Chamber and the Turkish Medical Oncology Association.
Dr. Sec treats breast, lung, gastrointestinal, prostate, urogenital, head and neck cancers, as well as sarcomas and rare tumors. He has published many peer-reviewed articles on cancer prognosis, treatment outcomes, and survival rates. His research includes studies with large patient groups, such as 138 patients with HER2-positive metastatic gastric cancer. Dr. Sec focuses on prognostic factors and treatment responses in different cancers. He is dedicated to improving cancer care.
患者様レビュー
医師のサービス
- PET-CT検査
- 生検
- MRI検査
- CT検査
- 腫瘍マーカー検査
- マンモグラフィ検査
- MRI検査
- 肺生検
- 乳房生検
- 甲状腺機能検査
- 胸部X線検査
- 卵巣生検
- 精巣生検
- 甲状腺生検
- 膵生検
- 肝生検
- 腎生検
- MRI検査
- 脳生検
- 胃内視鏡検査および生検
- 大腸内視鏡検査
- 血管造影検査
調子はいかがですか？
資格
Experience
2012-2017 Haseki Training and Research Hospital Internal Medicine
2017 Kanuni Sultan Süleyman Training and Research Hospital Internal Medicine Specialist Dr.
2017-2021 Prof. Dr. Cemil Taşcıoğlu City Hospital Medical Oncology
2021-2022 Şanlıurfa Mehmet Akif İnan EAH Medical Oncology Specialist Dr.
2022 Bahçelievler Medikalpark Hospital
2022- Turkish Medical Oncology Association Specialist Physicians Representative
Professional Memberships
1) Istanbul Medical Chamber Member
2) Turkish Medical Oncology Association Member
Areas of Interest
1) Breast cancer,
2) Lung cancer
3) Gastrointestinal (colon, rectum, stomach, liver) cancers
4) Prostate cancer
5) Urogenital cancers
6) Head, neck cancers
7) Sarcoma treatments
8) Rare tumors
Research and publications.
Prognostic significance of high free T4 and low free T3 levels in non-thyroidal illness syndrome
…, D Kayaş, ET Canbaz, F Çetin, Ş Seçmeler… - European journal of …, 2018 - Elsevier
Background Non-thyroidal illness syndrome is characterized by decreased serum free T3 (FT3)
level and associates with long term mortality. Serum free T4 (FT4) may affect mortality …
Clinical and pathological characteristics of patients with high-risk breast cancer based on BRCA mutation profiles: a retrospective study
…, S Ay, A Sakin, B Ertürk, Ş Selections… - European journal of …, 2021 - ncbi.nlm.nih.gov
Objective: This study aimed to determine the differences in clinicopathological features of
Turkish patients with high-risk breast cancer based on the mutation status of two breast cancer …
Prognostic significance of mean platelet volume on local advanced non-small cell lung cancer managed with chemoradiotherapy
A Sakin, S Secmeler, S Arici, C Geredeli, N Yasar… - Scientific reports, 2019 - nature.com
Mean platelet volume (MPV), the most commonly used measure of platelet size, and is altered
in patients with malignancies. The aim of this study was to investigate the effect of MPV on …
The predictive role of metabolic tumor volume on no response to neoadjuvant chemotherapy in patients with breast cancer
…, C Geredeli, R Cekin, Ş Selections… - Journal of Oncology …, 2020 - journals.sagepub.com
Introduction To evaluate the predictive significance of pretreatment metabolic tumor volume
on pathologic response in patients who received neoadjuvant chemotherapy for breast …
Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer
A Topcu, MM Atci, S Secmeler, M Besiroglu… - Future …, 2021 - Future Medicine
Aim: To evaluate the efficacy of trastuzumab and potential risk factors on survival in patients
with HER2-positive metastatic gastric cancer. Methods: We retrospectively included 138 …
The effects of diabetes and fasting plasma glucose on treatment of breast cancer with neoadjuvant chemotherapy
S Arici, C Geredeli, S Secmeler, R Cekin… - Current Problems in …, 2020 - Elsevier
Purpose To determine the effects of diabetes and fasting plasma glucose (FPG) level on the
pathologic response in patients with breast cancer who received neoadjuvant chemotherapy…
Major and minor salivary gland cancers: A multicenter retrospective study
…, NS Demirci, E Turkmen, T Şakalar, S Secmeler… - Head & …, 2023 - Wiley Online Library
Background Most of the studies on salivary gland cancers are limited for various reasons
such as being single‐center, small number of patients, including only major or minor SGCs, or …
Prognostic significance of primary tumor localization in stage II and III colon cancer
A Sakin, S Arici, S Secmeler, O Can… - World Journal of …, 2018 - ncbi.nlm.nih.gov
AIM To investigate the effects of tumor localization on disease free survival (DFS) and overall
survival (OS) in patients with stage II-III colon cancer. METHODS This retrospective study …
Factors affecting survival in neuroendocrine tumors: a 15-year single center experience
A Sakin, M Tambas, S Secmeler, O Can… - Asian Pacific Journal …, 2018 - ncbi.nlm.nih.gov
Background: Neuroendocrine tumors are a heterogeneous group of tumors that can originate
from all of the neuroendocrine cells in the body, mostly from the gastrointestinal tract. In…
The effect of body mass index on location of recurrence and survival in early-stage colorectal cancer
A Sakin, NS Samanci, S Secmeler, S Arici… - Journal of cancer …, 2020 - journals.lww.com
Materials and Methods: Patients that were followed up and treated in the Department of
Medical Oncology between 1999 and 2016 were retrospectively included in the study. patients…
Pretreatment Modified Glasgow Prognostic Score for Predicting Prognosis and Survival in Elderly Patients with Gastric Cancer Treated with Perioperative FLOT
E Melekoglu, E Bayram, S Secmeler, B Mete, B Sahin - Nutrients, 2023 - mdpi.com
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
こちらもご興味をお持ちいただけるかもしれません
支払い・特典
当社サービスへのお支払いはありません
クリニックで直接またはその公式銀行口座にお支払いいただきます。
一部のクリニックでは保証金が必要な場合があります。
分割払いオプションでお支払いを分散してください。
Bookimedにお友達を紹介して報酬を獲得してください。